Do you think Amarin intentionally delayed the EU submission to defer having to make a decision on an EU partner (and also to maximize their value to a potential buyer?)
Yes … as / considering: - EMA moved from London to Amsterdam in March (e.g.: "Europe’s drugs safety watchdog anticipated in summer 2018 that around 30% of its existing 900-strong workforce would not make the move to the Netherlands, but that figure has now been revised down to 24%" … it isn't recent, it is a Nov 2018 estimation) - pediatric waiver - requested "priority review" (was denied) - "clear" / close as many possible "issue" in the US